|
Gene: MAGEA10 |
Gene summary for MAGEA10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MAGEA10 | Gene ID | 4109 |
Gene name | MAGE family member A10 | |
Gene Alias | CT1.10 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | B2RAE8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4109 | MAGEA10 | ATC09 | Human | Thyroid | ATC | 2.07e-20 | 6.90e-01 | 0.2871 |
4109 | MAGEA10 | ATC13 | Human | Thyroid | ATC | 1.51e-42 | 7.64e-01 | 0.34 |
4109 | MAGEA10 | ATC1 | Human | Thyroid | ATC | 6.34e-23 | 7.84e-01 | 0.2878 |
4109 | MAGEA10 | ATC5 | Human | Thyroid | ATC | 2.22e-48 | 8.46e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | |
Thyroid | goiters | |
Thyroid | ATC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGEA10 | SNV | Missense_Mutation | novel | c.61N>C | p.Glu21Gln | p.E21Q | P43363 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MAGEA10 | SNV | Missense_Mutation | novel | c.842N>G | p.Leu281Arg | p.L281R | P43363 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
MAGEA10 | SNV | Missense_Mutation | c.1027N>A | p.Asp343Asn | p.D343N | P43363 | protein_coding | deleterious(0.01) | benign(0.01) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
MAGEA10 | SNV | Missense_Mutation | novel | c.314N>A | p.Ser105Tyr | p.S105Y | P43363 | protein_coding | deleterious(0) | possibly_damaging(0.599) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
MAGEA10 | SNV | Missense_Mutation | rs145553450 | c.20N>A | p.Arg7His | p.R7H | P43363 | protein_coding | tolerated(0.27) | benign(0.07) | TCGA-AA-3980-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEA10 | SNV | Missense_Mutation | c.47N>G | p.Leu16Arg | p.L16R | P43363 | protein_coding | tolerated(0.08) | possibly_damaging(0.519) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
MAGEA10 | SNV | Missense_Mutation | c.206G>A | p.Ser69Asn | p.S69N | P43363 | protein_coding | deleterious(0.04) | possibly_damaging(0.811) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MAGEA10 | SNV | Missense_Mutation | rs745481385 | c.1002G>C | p.Leu334Phe | p.L334F | P43363 | protein_coding | deleterious(0.02) | benign(0.198) | TCGA-DY-A1DF-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MAGEA10 | SNV | Missense_Mutation | novel | c.910G>A | p.Ala304Thr | p.A304T | P43363 | protein_coding | deleterious(0.04) | benign(0.342) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEA10 | SNV | Missense_Mutation | novel | c.418N>A | p.Asp140Asn | p.D140N | P43363 | protein_coding | tolerated(0.12) | benign(0.009) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |